These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18685491)

  • 1. Systematic review of HER2 breast cancer testing.
    Cuadros M; Villegas R
    Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):1-7. PubMed ID: 18685491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
    Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
    Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
    Diaz NM
    Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
    O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
    Arch Pathol Lab Med; 2008 Jan; 132(1):61-5. PubMed ID: 18181675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France.
    Morelle M; Haslé E; Treilleux I; Michot JP; Bachelot T; Penault-Llorca F; Carrère MO
    Int J Technol Assess Health Care; 2006; 22(3):396-401. PubMed ID: 16984069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC; Reimann JD; Anderson SM; Klein PM
    Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
    Roche PC; Suman VJ; Jenkins RB; Davidson NE; Martino S; Kaufman PA; Addo FK; Murphy B; Ingle JN; Perez EA
    J Natl Cancer Inst; 2002 Jun; 94(11):855-7. PubMed ID: 12048274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 status in breast cancer: experience of a Spanish National Reference Centre.
    Cuadros M; Cano C; López FJ; Talavera P; García-Peréz I; Blanco A; Concha Á
    Clin Transl Oncol; 2011 May; 13(5):335-40. PubMed ID: 21596662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples.
    Wang HY; Kim S; Park S; Kim S; Jung D; Park KH; Lee H
    Exp Mol Pathol; 2014 Dec; 97(3):368-74. PubMed ID: 25236569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
    Giltnane JM; Molinaro A; Cheng H; Robinson A; Turbin D; Gelmon K; Huntsman D; Rimm DL
    Arch Pathol Lab Med; 2008 Oct; 132(10):1635-47. PubMed ID: 18834223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of 2013 Updated ASCO/CAP HER2 Guidelines on the Diagnosis and Management of Invasive Breast Cancer: A Single-Center Study of 1739 Cases.
    Zhang X; Bleiweiss I; Jaffer S; Nayak A
    Clin Breast Cancer; 2017 Oct; 17(6):486-492. PubMed ID: 28433541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2--a discussion of testing approaches in the USA.
    Thor A
    Ann Oncol; 2001; 12 Suppl 1():S101-7. PubMed ID: 11521714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
    Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
    Blank PR; Schwenkglenks M; Moch H; Szucs TD
    Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.
    Dowsett M; Bartlett J; Ellis IO; Salter J; Hills M; Mallon E; Watters AD; Cooke T; Paish C; Wencyk PM; Pinder SE
    J Pathol; 2003 Apr; 199(4):418-23. PubMed ID: 12635131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.